key: cord-0826710-19skljon authors: Shah, A.; Gribben, C.; Bishop, J.; Hanlon, P.; Caldwell, D.; Wood, R.; Reid, M.; McMenamin, J.; Goldberg, D.; Stockton, D.; Hutchinson, S.; Robertson, C.; McKeigue, P. M.; Colhoun, H. M.; McAllister, D. title: Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households date: 2021-03-21 journal: nan DOI: 10.1101/2021.03.11.21253275 sha: f4f3931d5bddabc8096c77092530fa40fcb45881 doc_id: 826710 cord_uid: 19skljon Background: The effect of vaccination for COVID-19 on onward transmission is unknown. Methods: A national record linkage study determined documented COVID-19 cases and hospitalizations in unvaccinated household members of vaccinated and unvaccinated healthcare workers from 8th December 2020 to 3rd March 2021. The primary endpoint was COVID-19 >= 14 days following the first dose. Results: The cohort comprised of 194,362 household members (mean age 31.1 years) and 144,525 healthcare workers (mean age 44.4 years). 113,253 (78.3%) of healthcare workers received at least one dose of the BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccine and 36,227 (25.1%) received a second dose. Household members of vaccinated healthcare workers had a lower risk of COVID-19 case compared to household members of unvaccinated healthcare worker (rate per 100 person-years 9.40 versus 5.93; HR 0.70, 95% confidence interval [CI] 0.63-0.78). The effect size for COVID-19 hospitalization was similar, with the confidence interval crossing the null (HR 0.77 [0.53-1.10]). The rate per 100 person years was lower in vaccinated compared to unvaccinated healthcare workers for documented (20.13 versus 8.51; HR 0.45 [0.42-0.49]) and hospitalized COVID-19 (0.97 versus 0.14; HR 0.16 [0.09-0.27]). Compared to the period before the first dose, the risk of documented COVID-19 case was lower at >= 14 days after the second dose for household members (HR 0.46 [0.30-0.70]) and healthcare workers (HR 0.08 [0.04-0.17]). Conclusion: Vaccination of health care workers was associated with a substantial reduction in COVID-19 cases in household contacts consistent with an effect of vaccination on transmission. Over 200 candidate vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes coronavirus disease 2019 (COVID-19), have been developed. 1 Several of these have shown immunogenicity in phase 2 trials, [2] [3] [4] and three -ChAdOx1 nCoV-19, BNT162b2 mRNA and mRNA 1273 -have been shown to be effective in phase 3 trials and have been adopted for clinical use. 2, [5] [6] [7] [8] However, while a number of studies have demonstrated that some reduction of SARS-CoV-2 transmission following vaccination may be likely, 8, 9 neither clinical trials, nor post marketing studies have compared rates of infection among close contacts of vaccinated and unvaccinated individuals. As such, the magnitude of the effect of vaccination on transmission, which is crucial for pandemic planning and informing mass-vaccination strategies, 10 remains unknown. Previous real-world observational studies have demonstrated the effect of vaccination on rates of infection and hospitalisation with COVID-19 outside clinical trial settings. [11] [12] [13] However, studies examining hospitalisation did not account for occupational status, leaving the findings vulnerable to confounding by indication, since individuals in certain occupations (eg health and social care workers) are both eligible for early vaccination and at increased risk of COVID-19. Whereas the SIREN study, which did focus on a single occupational group -healthcare workerswas not large enough to examine hospitalisation. 9 As such, the effectiveness of vaccination on rates of hospitalisation outside clinical trial settings remains uncertain. In a nationwide study, we estimate the effect of vaccination on the risk of COVID-19 infection and hospitalisation in all healthcare workers andas a direct measure of the effect of vaccination on transmissionall members of their households. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint Healthcare workers were included if they were employed by the National Health Service (NHS) in Scotland on or before the 1 st of March 2020 (the first positive reported case of COVID-19 in Scotland) and still employed by the NHS on the 1 st of November 2020. Healthcare workers with a positive COVID-19 polymerase chain reaction (PCR) test before the 8 th December 2020 (the date when the vaccination programme was initiated) were excluded from the analysis. Data on healthcare workers and their household members were extracted and linked to multiple national datasets as previously described. In brief the Community Health Index (CHI) database, a registry of all patients registered to receive care from the NHS in Scotland (close to the complete population) was linked to the Scottish Workforce Information Standard System (SWISS) and General Practitioner Contractor Database (GPCD) databases. The CHI database was used to identify all individuals who were not themselves healthcare workers but shared a household with a healthcare worker. The healthcare worker and household data were then linked to multiple national databases including virology testing for SARS-CoV-2, general hospitalisation data, community prescribing, critical care admissions and the national register for deaths (Supplementary text 1 and Supplementary figure 1). 14 The healthcare worker cohort was restricted to the working-age population (18-65 years of age). The household member cohort included all ages but was restricted to households with no more than one healthcare worker (4% of healthcare workers lived in multiple healthcare worker households) (Supplementary figure 2) . . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint Outcomes were restricted to the time period from the 8 th December 2020 to 3 rd March 2021. The pre-specified primary outcome was any positive PCR test for SARS-CoV-2 (hereafter documented COVID-19). The secondary outcome was death or hospitalisation with COVID-19 defined hospitalisations/deaths where the recorded cause was COVID-19 (ICD-10 U07•1,U07•2 or U07•5) or any hospitalisation/death occurring within 28 days of a first positive test or having first tested positive while in hospital. Where hospitalisation or death occurred without any positive test (only five and three events in healthcare workers and household members respectively), the event date was presumed to have occurred 14 days prior to the date of hospitalisation and/or death. The exposure was defined when a healthcare worker received the first dose of the BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccine (the only two vaccines approved for clinical use at that time in the UK). A second dose of these vaccines was studied as a separate exposure. Covariates were obtained from nationwide databases as previously described. 14 Health board area was included as a stratifying variable, and other variables identified as potential risk factors for COVID-19 were included as covariates in regression models; age, sex, Scottish is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint The statistical analysis was pre-specified prior to linking the outcome and vaccination data (http://www.encepp.eu/encepp/viewResource.htm?id=39737, https://github.com/dmcalli2/hcw_vax). Person-time at risk was defined as the period from the 8th December 2020 to the date of the target event, death from a non-COVID-19 cause, or the end of follow-up (3rd March 2021), whichever came first. If household members were themselves vaccinated, person-time was censored on the day of their vaccination. Vaccination status was encoded as a time-varying categorical variable with three levels, defined with respect to the date of the first doseunvaccinated for all days prior, intermediate for days 1 to 13, and post-dose from day 14 onwards. For additional analyses examining the effect of the second dose, we added a further level -14 days onward from the second dose . Extended Cox regression models were used to estimate hazard ratios (HRs) for the effect of vaccination on both cases and hospitalisation, calculating robust standard errors to allow for clustering due to shared household membership and stratifying on health board area to allow for regional differences in baseline hazard. Hazard ratios were reported unadjusted and then adjusted sequentially for socio-demographic, occupational and comorbidity covariates. Cox regression, with calendar time as the timescale, eliminates the baseline hazard rate and thus makes it unnecessary to model how the rate of COVID-19 varies over calendar time. The pre-specified primary comparison was the HR for documented cases in the period 14 days onward from the first dose compared to unvaccinated person time (i.e. before day 1 of vaccination). We also report pre-specified secondary analyses for the HRs associated with vaccination status at 7-day intervals from the date of vaccination. Analyses were performed in R Version (3•6•1). . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint The cohort comprised 194,362 household members (mean age 31•1±20•9) and 144,525 healthcare workers (mean age 44•4±11•4 years) ( Table 1) There were 3,123 documented COVID-19 cases and 175 hospitalisations in household members of healthcare workers. In the fully adjusted models (Table 2) , for the pre-specified primary comparison (comparing the 14-day onwards post-dose period to the unvaccinated period), vaccinating the co-habiting healthcare worker was associated with a reduced risk of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint magnitude were observed for COVID-19 hospitalisations (rate per 100 person-years: 0•51 versus 0•31; HR 0•77, 95%CI 0•53-1•10) although the wider confidence intervals included the null. In our previous report we showed that household members of patient facing healthcare workers were at a 2-fold higher risk of hospitalisation than individuals who did not share a household with a healthcare worker, i.e. at most half of all cases in household members are attributable to exposure to the health care worker and therefore preventable by preventing transmission from the health care worker. 14 Thus, the 30% reduction which we observed for all cases is consistent with a 60% reduction in preventable cases (Supplementary table 1) . If the true effect of sharing a household with a healthcare worker is lower than we previously report, the true reduction in preventable cases due to vaccination will be higher than 60%, and the converse is also true. In stratified analyses there was no evidence of heterogeneity in effect of vaccination by age, sex, or socio-economic deprivation of the household members or by the occupational role of the healthcare worker (Figure 1 ). In the immediate period (day 1-6) following the first dose, there was a lower risk of events, but by day 7-14 there was no difference in risk associated with vaccination. Subsequent to this, vaccination was again associated with a reduced risk that became more marked with longer follow up; the associations increased in magnitude from day 14 onwards with the largest differences seen after 28 days following vaccination, HR 0•64 (95%CI 0•56-0•73) and 0•64 (95%CI 0•40-1•01) for documented cases and hospitalisations respectively, Table 3 ). . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (Table 4) . There were 4,343 documented cases and 177 COVID-19 hospitalisations in healthcare workers ( Table 2 ). The effect on the hospitalisation rates was Figure 1) . As for household members, the differences were larger in the later period following vaccination ( Table 3) . Compared to the unvaccinated period, the hazard ratio for the 14-days onwards post-second dose period was larger (HR 0•08 [95%CI 0•04-0•17]; rate per 100 person years 20•13 versus 1•17). There were no hospitalisations in healthcare workers who received a second dose of the vaccine and as such the hazard ratio for this period could not be estimated ( Table 4) . . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint This study examined the impact of a nationwide vaccination programme on the risk of COVID-19 in healthcare workers and their household members. We found that vaccination appeared to reduce transmission. Among household members of vaccinated healthcare workers there was a 30% reduction in documented cases from day 14 post vaccination with similar, albeit not statistically significant, reductions in hospitalisation. Consistent with previous reports, 9 we also found a lower risk of documented cases and hospitalisation in the 1-7 day period immediately following the first dose. This occurred in both healthcare workers and their household members. Since it is too early for this to be is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint Since household members of healthcare workers can also be infected via other routes, this 30% relative risk reduction is an underestimate of the 'true' effect of vaccination on transmission. Had all cases among household members originated from the healthcare worker with whom they lived, the 30% relative risk reduction would represent a valid estimate. However, since not all cases in a household come via the healthcare worker (based on our previous estimates the proportion is closer to half) 14 , not all cases in this group can be prevented by vaccinating healthcare workers. As such, the proportion of cases prevented by vaccinating healthcare workers which do arise via exposure to that healthcare worker, must be considerably larger and estimated at 60% in our analysis. Despite a lack of previous empirical studies of transmission, this finding is biologically plausible. Vaccination reduces asymptomatic carriage of SARS-CoV-2, as has been shown in a 17,000 participants phase 3 clinical trial of the ChAdOx1 nCoV-19 vaccine, as well as in the SIREN study of healthcare workers. 8, 9 This provides a mechanistic rationale for the reduction in risk in household members, even in the absence of symptomatic infection in healthcare workers. Kingdom changed the vaccine policy to increase the time interval between doses. Despite this, just over 25,000 healthcare workers received a second dose, which allowed us to examine the differential impact of a second dose of vaccination on transmission and infection. The relative difference in documented cases and hospitalisation in household members following the . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint second dose was at least as large as the difference after the first dose, although for hospitalisations the numbers were small and the confidence intervals wide. Our findings are consistent with previous studieswhich did not study transmission -with respect to the direct effect on infection and hospitalisation those individuals vaccinated. 8, 9 To these studies which adjusted for a range of potential confounders, we add detailed information on occupational status. This extends previous findings since occupation is an important potential confounder as it predicts infection risk and determines access to vaccination. Our results are also consistent with the 23,324 participant SIREN study which examined risk of symptomatic and asymptomatic infections, but not hospitalisation. 9 We add effect estimates in a homogeneous cohort with detailed occupational information which is also sufficiently large to examine the effect of vaccination on hospitalisation-confirming the large decline in both documented infection and hospitalisation in addition to the impact of vaccination on transmission. Our existing cohort of healthcare workers and their household members provided an ideal opportunity to address the question of the effect of vaccination on transmission; transmission is commoner in households than in any other setting, 15 healthcare workers and their household members are at increased risk of COVID-19 enriching the cohort for events, 14 and healthcare workers have been prioritised for early-vaccination allowing this question to be addressed rapidly. Nevertheless, several points need to be considered when interpreting our results. First, the healthcare workers in our analysis were aged between 18 and 65 years of age. We are therefore unable to evaluate the impact on vaccinating elderly or vulnerable individuals. Secondly, differences in individual behaviour concerning testing before and after vaccination . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint could introduce bias. However, this seems an unlikely explanation for our findings since similar results were seen for hospitalisation, consistent results were obtained following the first and second dose, the differences became larger over time which is biologically plausible and the direction of effect were similar in both household members and healthcare workers. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint Vaccinating healthcare workers for SARS-CoV-2 reduces documented cases and hospitalisation in both those individuals vaccinated and members of their households. This is reassuring for healthcare workers, and has wide reaching implications for vaccination strategies and societal control measures. . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint Table and Figures Table 1 : Baseline characteristics of vaccinated and unvaccinated healthcare workers and their households by month of first dose in the healthcare workers Table 2 : Effect of vaccination in healthcare workers on documented COVID-19 cases and hospitalisations in healthcare workers and their households: unvaccinated period versus period from 14-days post first dose Table 3 : Effect of vaccination in healthcare workers on documented COVID-19 in healthcare workers and their household at multiple time periods following the first dose Table 4 : Effect of second dose vaccination in healthcare workers on documented COVID-19 cases and hospitalisations in healthcare workers and their households: unvaccinated period versus periods from 14-days post second dose Table 2 Funding and Acknowledgements is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2021. ; https://doi.org/10.1101/2021.03.11.21253275 doi: medRxiv preprint Draft landscape of COVID-19 candidate vaccines Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study) BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunisation: real-world evidence Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study Age (mean (SD)), years Abbreviations: AGP -Aerosolized generating procedure; SIMD -Scottish Index of Multiple Deprivation